Day 100
prognostic factors post-autologous peripheral blood hematopoietic stem cell
transplantation (APBHSCT) to predict clinical outcomes in diffuse large B-cell
lymphoma (DLBCL) patients have not been studied. Thus, we retrospectively
examined if day 100 absolute monocyte/lymphocyte prognostic score (AMLPS-100)
affects clinical outcomes by landmark analysis from day 100 post-APBHSCT in
DLBCL. Only DLBCL patients in complete remission at day 100 post-APBHSCT were
evaluated. From 2000 to 2007, 134 consecutive DLBCL patients are qualified for
the study. Patients with a day 100 absolute monocyte count (AMC-100) ≥ 630
cells/μL and day 100 absolute lymphocyte count (ALC-100) ≤ 1000 cells/μL experienced
inferior overall survival (OS) and progression free survival (PFS). On multivariate
analysis, the AMC-100 and ALC-100 remained independent predictors of OS and
PFS. Combining both values into the AMLPS-100, the 5-year OS rates for low,
intermediate, and high AMLPS-100 risk groups were 94% (95% CI, 83.0% - 98.1%),
70% (95% CI, 58.6% - 80.1%), and 13% (95% CI, 3.4% - 40.5%), respectively; and
the 5-year PFS rates were 87% (95% CI, 74.0% - 94.1%), 68% (95% CI, 56.0% - 77.8%),
and 13% (95% CI, 3.4% - 40.5%), respectively. The AMLPS-100 is a simple
biomarker score that can stratify clinical outcomes from day 100 post-APBHSCT
in DLBCL patients.